Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
Jose W. Ricardo, Shari R. Lipner
Abstract
Regulatory agencies across the globe had given emergency use authorization of the highly effective Pfizer-BioNTech COVID-19 messenger RNA (mRNA) vaccine (BNT162b2) in view of the ongoing COVID-19 pandemic. In phase 3 trials, the vaccine, which uses an mRNA platform encoding the spike glycoprotein of SARS-CoV-2, confers 52% protection against COVID-19 12 days following the first dose and 95% protection after the second dose, if administered 3 to 4 weeks apart in individuals without previous SARS-CoV-2 infection.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Messenger RNASevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakAuthorizationPandemicOutbreakBiologyPathologyGeneticsInfectious disease (medical specialty)GeneComputer securityDiseaseComputer scienceSARS-CoV-2 and COVID-19 ResearchDermatological and COVID-19 studiesImmunotherapy and Immune Responses